Key Takeaways Mesenchymal stem cells are among the most studied cell types for chronic liver disease, but the approach is still experimental. Researchers think the cells may calm the immune system and slow scar-forming cells, mostly based on lab and animal work. Small human trials reported better survival in some
Key Takeaways The liver can repair itself to a point, but chronic liver diseases like cirrhosis eventually overwhelm that natural ability. Mesenchymal stem cell therapy is being studied as a supportive option, working mainly through anti inflammatory and immune-calming effects. One randomized trial found a real survival benefit in patients
Quick Summary A 2026 Nature study (MATCH trial) shows autologous macrophage therapy may improve transplant‑free survival in cirrhosis. After 4 years, ~70% of treated patients were alive without liver transplant vs. ~40% in standard care. The treatment uses the patient’s own immune cells (macrophages) to reduce inflammation and support repair.
